Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam monotherapy for childhood or juvenile absence epilepsy
2020-002750-24Phase 2Completed
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) comparing Brivaracetam monotherapy with Placebo (2 arms). Primary endpoint: Absence seizure freedom at Day 14. Started Dec 2020; status: completed.
02
Drugs
brivaracetam
03
Conditions
childhood absence epilepsy (CAE)juvenile absence epilepsy (JAE)
Beyond the preview
Go deeper on 2020-002750-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002750-24.